<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386487</url>
  </required_header>
  <id_info>
    <org_study_id>2000022450</org_study_id>
    <nct_id>NCT03386487</nct_id>
  </id_info>
  <brief_title>Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)</brief_title>
  <acronym>FAAH-I MULTI</acronym>
  <official_title>A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to
      Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH)
      Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy, safety and tolerability of the FAAH Inhibitor PF-0447845 in reducing cannabis
      use will be studied in a 4-site randomized, double-blind, placebo-controlled, parallel-group,
      outpatient clinical trial comparing PF-04457845 (4mg) and placebo in DSM-5 CUD individuals.
      Participants will be randomized in a 1:1 ratio to either PF-04457845 or placebo using random
      block sizes of 2 and 4, stratified by site and degree of cannabis use. Participants will
      receive motivational interviewing for 2 weeks before being randomized to receive study
      medication to make a quit attempt within the first week of treatment. Participants will
      receive active or placebo PF-04457845 for 8 weeks during which time they will be evaluated
      weekly in face to face visits. In addition, daily assessment of adherence to study medication
      and cannabinoid use will be conducted daily by cellphone. Measures of cannabinoid exposure
      (self-reported and urine toxicology), and problems related to the use of cannabis, will be
      assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2B</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Line Follow Back (TLFB) for cannabis use</measure>
    <time_frame>Change from baseline in weekly self reported cannabis use as measured by the TLFB at baseline and then weekly over 8 weeks</time_frame>
    <description>Change in the average number of times per day of self-reported cannabis consumption measured by the 7 day Timeline Follow Back approach for Cannabis Use in which participants quantify and report their frequency of cannabis use prior to study participation and throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary levels of THC-COOH (ng/ml)</measure>
    <time_frame>Change from baseline in weekly levels of urinary THC-COOH levels over 8 weeks from urine samples collected at baseline and each weekly visit</time_frame>
    <description>Assay of the levels of the principal metabolite of THC (THC-COOH) in urine samples collected from the participants at each weekly visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">237</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF 04457845</intervention_name>
    <description>Study medication will be administered at 4mg by mouth daily for eight weeks.</description>
    <arm_group_label>PF-04457845</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo comparator will be administered by mouth daily for eight weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 18-60 years, inclusive.

          2. Male or Female.

          3. Individuals with DSM-V criteria for Cannabis Use Disorder .

          4. Positive for urinary THC-COOH at both screening visits.

          5. Must express a willingness at screening to set a date within the first week of
             randomization to attempt to quit using cannabis.

        Exclusion Criteria:

          1. Clinically significant unstable medical disorders (as determined by the site
             investigator).

          2. Laboratory tests with clinically significant abnormalities (as determined by the site
             investigator)

          3. Pregnancy by history and or laboratory confirmation (serum HCG).

          4. Lactation.

          5. Physiological dependence on another substance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak C D'Souza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Luddy, BS</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4549</phone_ext>
    <email>christina.luddy@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Selloni, BA</last_name>
      <phone>203-974-7544</phone>
      <email>alexandria.selloni@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberlee Forselius-Bielen, BS</last_name>
      <phone>203-974-7540</phone>
      <email>kimberlee.forselius@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deepak C D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohini Ranganathan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elia Goffi, BS</last_name>
      <phone>410-550-0050</phone>
      <email>egoffi2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Vandrey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dustin Lee, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical College / New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Mahony, LMHC</last_name>
      <email>amy.mahony@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Frances Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Wagner, MA, LPC</last_name>
      <phone>843-792-0484</phone>
      <email>wagne@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aimee McRae-Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Deepak C. D'Souza</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

